Pfizer Inc. (PFE)
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Pfizer (PFE) reports positive mid-stage trial data for berobenatide, aiming to be the first GLP-1 obesity therapy with monthly dosing. PFE plans up to 10 Phase 3 trials for berobenatide, targeting long-term obesity management and related conditions.
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Monday.
3 Dividend Stocks to Buy Hand Over Fist in June
Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well. UPS has turned away from Amazon.com and toward more profitable deliveries.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's weekly injection Wegovy.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
L
Pfizer vs Merck: Chasing High Yield vs Higher Returns
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Why Pfizer's Current Price May Be Too Cheap to Ignore
Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
